Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide for Type 1 Diabetes on Closed-Loop Insulin Therapy
NCT06387199Phase 3Recruiting
- Sponsor
- McGill University Health Centre
- Start
- Dec 2024
- Primary completion
- Jan 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of semaglutide in type 1 diabetes mellitus (T1D), sponsored by McGill University Health Centre. Started Dec 2024; status: recruiting.
02
Drugs
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT06387199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06387199.